Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule.
The Phase 1 trial is a double-blind, randomized, placebo-controlled study investigating the safety, tolerability, and pharmacokinetics of single, subcutaneous dose of the compound, called FT-104 HCl, in healthy volunteers.
The trial, conducted at PARC Clinical Research at the Royal Adelaide Hospital in Australia, involves Field Trip's first proprietary molecule, FT-104, which is a prodrug of 4-OH-DiPT, a synthetic serotonin-2A (5HT2A) agonist, similar to LSD, psilocybin and DMT.
Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin, but with a significantly shorter half-life of approximately three hours.
The FT-104 pre-clinical profile projects a reduced treatment burden. Based on that and promising results from the early psilocybin …